e-learning
resources
Munich 2014
Sunday, 07.09.2014
Rationale behind respiratory drug development
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparison of the particle size distribution of fluticasone propionate/formoterol and beclometasone/formoterol MDI using laser diffraction
P. Haidl, G. Scheuch, C. Kietzig, D. Kappeler, R. Cloes (Schmallenberg-Grafschaft, Gemuenden/Wohra, Gauting, Limburg/Lahn, Germany)
Source:
International Congress 2014 – Rationale behind respiratory drug development
Session:
Rationale behind respiratory drug development
Session type:
Thematic Poster Session
Number:
939
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Haidl, G. Scheuch, C. Kietzig, D. Kappeler, R. Cloes (Schmallenberg-Grafschaft, Gemuenden/Wohra, Gauting, Limburg/Lahn, Germany). Comparison of the particle size distribution of fluticasone propionate/formoterol and beclometasone/formoterol MDI using laser diffraction. Eur Respir J 2014; 44: Suppl. 58, 939
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Plume temperature and force of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014
In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
In vitro
analysis of two formulations of fluticasone/ salmeterol pMDI for delivered dose uniformity and aerodynamic particle size distribution
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
The effect of inhalation duration on lung deposition with a pressurized metered-dose inhaler (pMDI)
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Effects of extra fine formoterol or coarse particle salmeterol on impulse oscillometry (IOS) in corticosteroid treated persistent asthmatics
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Are extra-fine particles from dry powder inhalers likely to improve lung deposition?
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Are ultrafine particle inhalers, better for patients with small airway involvement?
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014
The performance of a new vibrating mesh prototype nebulizer for inhaled biodrugs
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
Efficacy and safety of indacaterol acetate on ICS background therapy in asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Effect of interval between actuations of albuterol HFA inhalers on their aerosol characteristics
Source: International Congress 2016 – Paediatric asthma: recurrent, persistent, or severe obstruction and lung function techniques
Year: 2016
Effects of combining tiotropium and salmeterol/fluticasone propionate on airway dimensions in patients with COPD
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013
Comparative effectiveness analysis: Extra-fine particle hydrofluoroalkane beclomethasone dipropionate vs fluticasone propionate with spacer in children
Source: Annual Congress 2013 –Treatment and management of asthma in primary care
Year: 2013
Late Breaking Abstract - Lung deposition of two different ICS/LABA combinations with Dry Powder Inhaler (DPI) in asthmatic patients using Functional Respiratory Imaging (FRI).
Source: International Congress 2019 – Imaging for prognostication and disease characterisation: 2019 update
Year: 2019
Plume characteristics of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
Study design supporting the effectiveness of inhaled extra-fine beclomethasone/formoterol at the level of small airways of asthmatics
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
Mixed treatment analysis comparing tiotropium HandiHaler
®
and Respimat
®
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Quantitative computed tomography assessment of airway dimensions by combining tiotropium and indacaterol in patients with COPD
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014
Device handling study of a novel fluticasone propionate/formoterol breath-triggered inhaler
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept